Free priority shipping over $200 · Same-day dispatch from Miami, FL

AlphaPepLab

RESEARCH USE ONLY. All AlphaPepLab compounds are for in-vitro laboratory research. Not for human or veterinary use, diagnosis, or consumption.

Tirzepatide
Purity 99.96%
Metabolic Research

Tirzepatide

Dual GLP-1/GIP Receptor Co-Agonist

C₂₂₅H₃₄₈N₄₈O₆₈ · 4,813.5 Da

COA Verified Third-party tested
Verify to see price/ 10mg
1

GIP-based dual agonist incorporating a GLP-1 receptor-binding motif. Features a C20 fatty diacid moiety enabling reversible albumin binding and extended circulatory half-life.

Form
Lyophilized powder
Purity
99.96%
Stock
In stock
Sizes available
10mg
≥99% verified 48h US shipping Secure checkout
RESEARCH USE ONLY. This product is intended strictly for in-vitro laboratory research. Not for human or veterinary use, diagnosis, or consumption.

Specification

Sizes available
10mg ($64.95)
Form
Lyophilized powder
Category
Metabolic Research
Molecular class
Dual GLP-1/GIP Receptor Co-Agonist
Molecular formula
C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight
4,813.5 Da
Purity
99.96%

Certificate of Analysis

Test Method
LCMS-UV
Laboratory
ACS Peptide Testing Labs
Test Date
2026-07-28
Download COA (PDF)
Scientific description

Composition, targets and analytical record

The structural record for the material as supplied, and the analytical figures returned for the lot on the certificate.

Residues
39
Formula
C₂₂₅H₃₄₈N₄₈O₆₈
Average mass
4,813.5 Da
Monoisotopic
4810.52 Da

Tirzepatide is a synthetic 39-residue peptide of molecular formula C₂₂₅H₃₄₈N₄₈O₆₈, with an average molecular mass of 4813.53 Da and a monoisotopic mass of 4810.5249 Da. The sequence opens Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr and closes Gly-Ala-Pro-Pro-Pro-Ser as a C-terminal amide. Alpha-aminoisobutyric acid, a non-proteinogenic alpha,alpha-disubstituted residue, occupies positions 2 and 13; every other position is proteinogenic.

N-terminus → C-terminus39 positions
  1. 1Tyr
  2. 2Aib
  3. 3Glu
  4. 4Gly
  5. 5Thr
  6. 6Phe
  7. 7Thr
  8. 8Ser
  9. 9Asp
  10. 10Tyr
  11. 11–12
  12. 13Aib
  13. 14–19
  14. 20Lys
  15. 21–33
  16. 34Gly
  17. 35Ala
  18. 36Pro
  19. 37Pro
  20. 38Pro
  21. 39Ser
Aib · 2, 13Lipidated · 20range not named in the record
Fig. 1 — Sequence landmarks. Only positions named in the record are shown; intervening ranges are marked ⋯.

The epsilon-amine of Lys20 carries a branched acyl assembly consisting of an eicosanedioic (C20 alpha,omega-dicarboxylic) acyl group linked through a gamma-glutamate spacer and two consecutive 2-[2-(2-aminoethoxy)ethoxy]acetyl (AEEA) units. That assembly contributes C₃₇H₆₅N₃O₁₂ to the intact composition, the unmodified backbone accounting for the remainder. Assembling the formula from the sequence and the four amide bonds of the acyl-spacer chain reproduces the deposited formula atom for atom, which provides an internal check on both the sequence assignment and the substitution site.

Acyl-spacer assembly
01
Eicosanedioic acyl
02
γ-Glutamate
03
AEEA × 2
04
Lys20 ε-amine
Backbone (by difference)C₁₈₈H₂₈₃N₄₅O₅₆+SubstituentC₃₇H₆₅N₃O₁₂=Intact moleculeC₂₂₅H₃₄₈N₄₈O₆₈
Fig. 2 — The assembly carried on the named residue, and the composition it contributes.

The molecule belongs to the incretin-family peptide analogues of the glucagon/secretin peptide superfamily. Two receptor entries are named against it: the gastric inhibitory polypeptide receptor (UniProt P48546) and the glucagon-like peptide 1 receptor (UniProt P43220). It is described in ChEMBL as a dual GIP and GLP-1 receptor agonist peptide.

Structurally the compound is separated from retatrutide by the position and composition of its lipid substituent, Lys20 with two AEEA spacer units against Lys17 with one, and by position 13, which is alpha-aminoisobutyric acid here and alpha-methyl-leucine in retatrutide. It is separated from the native 42-residue gastric inhibitory polypeptide by length, by the two Aib substitutions, by the C-terminal amide and by the presence of the acyl chain, none of which occur in the native sequence. The 82.11 Da average-mass gap to retatrutide and the far larger gap to unmodified incretin sequences make identity assignment by mass spectrometry straightforward.

Acyl chain attachment
RetatrutideLys17
TirzepatideLys20
AEEA units in spacer
Retatrutide1
Tirzepatide2
Position 13
Retatrutideα-methyl-Leu
TirzepatideAib
Compositional Δ · C₄H₆N₂ · 82.11 Da average · resolvable by ESI-MS
Fig. 3 — The counts on which this compound and its closest structural relative separate.

Analytical specification

ACS Peptide Testing Labs · 2026-07-28 · AAHW066
Purity
99.96%
Identity
Confirmed (LCMS-UV mass ID)
Appearance
White powder
Endotoxin
N/A

The lot supplied for Tirzepatide was assayed by ACS Peptide Testing Labs on 2026-07-28 under accession AAHW066. Purity is reported as 99.96% by LCMS-UV, expressed as the percentage of total UV peak area attributable to the target compound. Identity is a separate determination and was returned as: Confirmed (LCMS-UV mass ID). A sample can be highly pure and still be the wrong molecule, which is why both results appear on the certificate.

The material was recorded as White powder. The sequence corresponds to a molecular formula of C₂₂₅H₃₄₈N₄₈O₆₈ and a calculated mass of 4,813.5 Da.

Endotoxin was outside the scope of this assay and is reported as N/A. Peak-area percentage is also not the same as absolute mass purity: material that does not absorb at the detection wavelength is not represented in the figure.

Read the full certificate

This material is supplied strictly for in-vitro laboratory research. It is not a drug, food or supplement, and is not for human or veterinary use, diagnosis, or consumption.

Related compounds

View catalog